Pharmaceutical Editorial
  • Home
  • News
  • About
  • Contact

Versa HD™ – Elekta Sets New Benchmark for Cancer Treatment with Launch of Versa HD System

Cancer, Elekta, Medical, Pharmaceuticals, Press Releases, Surgical

Versa HD is not available for sale or distribution in all markets. Elements of Versa HD are pending FDA 510(k) clearance. – See more at: http://www.versahd.com

Versatility to deliver better treatments to more patients
Versa HD gives clinicians the flexibility to deliver conventional therapies to treat a wide range of tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision. As an integrated treatment system, Versa HD offers the versatility to address today’s growing cancer management challenges.

“The well-being of increasing numbers of cancer patients worldwide inspired us to create Versa HD,” says Elekta’s President and CEO, Tomas Puusepp. “We strived to incorporate technologies that would provide an immediate impact to patient health and quality of life. As the pioneers of many of today’s most advanced therapies, we are proud to introduce Versa HD as yet another market-leading innovation. Versa HD truly reflects the best thinking of Elekta’s technical experts and our clinical partners.”

Integrated with Elekta’s recently-launched Agility™ 160-leaf multileaf collimator (MLC), Versa HD provides highly conformal beam shaping — a critical requirement for maximizing the dose to the target while also preserving surrounding healthy tissues. Importantly, this high targeting accuracy is available over a large field-of-view, permitting delivery of high-definition (HD) beams to a wide spectrum of complex targets. Historically, high-definition beam shaping often was mechanically limited to only small target therapies. Versa HD with Agility overcomes this challenge, now empowering clinicians to deliver extremely precise beam contouring for both small and large targets.

SOURCE: Elekta

Related Posts

Medical, Pharmaceutical, Pharmaceuticals, Press Releases

Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting

Allergan, Medical, Pharmaceutical, Pharmaceuticals, Press Releases

Allergan’s Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications

Medical, Pharmaceutical, Pharmaceuticals, Press Releases

The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures

Featured News

  • Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting
  • Allergan’s Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications
  • The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures
  • Abbott Announces CE Mark for Tacticath™ Contact Force Ablation Catheter, Sensor Enabled™
  • Abbott Announces CE Mark and First Use of the World’s First SmartPhone Compatible Insertable Cardiac Monitor
Pharmaceutical Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!